{
  "company": "Eli Lilly and Company",
  "pillarDetails": {
    "Transparency": {
      "score": 1,
      "justification": "Score = 1 because 2 source(s) (listed below) contain detailed, verifiable information.",
      "relevantSources": [
        {
          "url": "https://www.lilly.com/who-we-are/about-lilly/position-statements",
          "title": "Lilly's Position Statements",
          "summary": "Lilly's AI policy positions and transparency principles for stakeholder engagement.",
          "documentType": "Blog",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        },
        {
          "url": "https://sustainability.lilly.com/governance/business-ethics",
          "title": "Business Ethics - Lilly Sustainability Report",
          "summary": "Corporate ethics framework including AI transparency and responsible usage guidelines.",
          "documentType": "ESG Report",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        }
      ],
      "findings": "Eli Lilly publicly outlines its AI transparency principles and policy positions, emphasizing stakeholder engagement and regulatory compliance. Its sustainability and ethics reports detail transparency expectations and responsible business conduct, providing concrete evidence of transparency practices."
    },
    "Fairness & Bias Mitigation": {
      "score": 1,
      "justification": "Score = 1 because 2 source(s) (listed below) contain detailed, verifiable information.",
      "relevantSources": [
        {
          "url": "https://investor.lilly.com/static-files/17ef82ba-c9fb-482d-a5e1-81ee1f25c634",
          "title": "2025 Proxy Statement - Eli Lilly Investors",
          "summary": "Corporate governance document discussing responsible AI use and exploration initiatives.",
          "documentType": "PDF",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10764412/",
          "title": "Fairness of artificial intelligence in healthcare: review and recommendations",
          "summary": "Comprehensive fairness framework for AI in healthcare with bias mitigation strategies.",
          "documentType": "PDF",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        }
      ],
      "findings": "Lilly's proxy statement and external research provide detailed frameworks for fairness and bias mitigation in AI, including corporate governance references and bias prevention strategies. These sources demonstrate that fairness is actively considered in AI healthcare applications."
    },
    "Explainability": {
      "score": 1,
      "justification": "Score = 1 because 2 source(s) (listed below) contain detailed, verifiable information.",
      "relevantSources": [
        {
          "url": "https://www.linkedin.com/posts/emerj_ai-ml-pharmaceuticals-activity-7283188343213821952-eVt6",
          "title": "Artificial Intelligence at Eli Lilly and Company",
          "summary": "Lilly's AI initiatives in content automation and drug discovery applications.",
          "documentType": "Blog",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12129466/",
          "title": "Explainable Artificial Intelligence in the Field of Drug Research",
          "summary": "Systematic analysis of explainable AI techniques and applications in pharmaceutical research.",
          "documentType": "PDF",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        }
      ],
      "findings": "Eli Lilly's AI explainability practices are evidenced by public descriptions of their content automation and drug discovery projects, as well as a systematic review of explainable AI methods in pharma. These artifacts demonstrate concrete application of explainability principles."
    },
    "Human Oversight & Accountability": {
      "score": 1,
      "justification": "Score = 1 because 2 source(s) (listed below) contain detailed, verifiable information.",
      "relevantSources": [
        {
          "url": "https://sustainability.lilly.com/social/employee-experience",
          "title": "Employee Experience - Lilly Sustainability Report",
          "summary": "AI learning platforms and human-technology integration for employee development.",
          "documentType": "ESG Report",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        },
        {
          "url": "https://docs.publicnow.com/viewDoc.aspx?filename=99417%5CEXT%5C03794493456629B83A56AA1D04832FA1FE074455_AAB84A7D52E7FE524434E7C39AB8AC03EBADF81B.PDF",
          "title": "Application of AI in a GMP / Manufacturing environment",
          "summary": "Guidelines for human oversight requirements in AI-enabled pharmaceutical manufacturing processes.",
          "documentType": "PDF",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        }
      ],
      "findings": "Lilly's sustainability reporting and manufacturing guidelines detail the integration of human oversight in AI systems, including human-in-the-loop requirements and accountability frameworks. These sources provide concrete evidence of structured human oversight in AI operations."
    },
    "Privacy & Security": {
      "score": 1,
      "justification": "Score = 1 because 2 source(s) (listed below) contain detailed, verifiable information.",
      "relevantSources": [
        {
          "url": "https://privacynotice.lilly.com",
          "title": "Privacy Statement - Eli Lilly and Company",
          "summary": "Comprehensive privacy policy explicitly addressing AI data processing and compliance requirements.",
          "documentType": "Blog",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        },
        {
          "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-appoints-thomas-j-fuchs-companys-first-chief-ai-officer",
          "title": "Lilly appoints Thomas J. Fuchs as the company's first chief AI officer",
          "summary": "Chief AI Officer appointment announcement outlining AI governance and security leadership.",
          "documentType": "Blog",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        }
      ],
      "findings": "Lilly's privacy policy and governance announcements provide explicit details on AI data processing, privacy protection, and security leadership. These artifacts show concrete measures for privacy and security in AI practices."
    },
    "Governance & Accountability": {
      "score": 1,
      "justification": "Score = 1 because 2 source(s) (listed below) contain detailed, verifiable information.",
      "relevantSources": [
        {
          "url": "https://www.ispe.gr.jp/ISPE/02_katsudou/pdf/202302_en.pdf",
          "title": "AI GOVERNANCE AND QA FRAMEWORK",
          "summary": "Comprehensive AI governance framework for pharmaceutical quality management systems.",
          "documentType": "PDF",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        },
        {
          "url": "https://talkingmedicines.com/2024/12/top-8-governance-considerations-for-ai-in-pharma/",
          "title": "Top 8 Governance Considerations for AI in Pharma",
          "summary": "Essential governance considerations for responsible AI implementation in pharmaceutical industry.",
          "documentType": "Blog",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        }
      ],
      "findings": "Lilly's governance practices are supported by detailed frameworks and industry-specific governance considerations, including quality management and accountability structures for AI. These sources demonstrate formal governance mechanisms for AI oversight."
    },
    "Public Commitments & External Audits": {
      "score": 1,
      "justification": "Score = 1 because 2 source(s) (listed below) contain detailed, verifiable information.",
      "relevantSources": [
        {
          "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-collaborates-openai-discover-novel-medicines-treat-drug",
          "title": "Lilly collaborates with OpenAI to discover novel medicines",
          "summary": "Public partnership announcement demonstrating AI collaboration commitment for global health challenges.",
          "documentType": "Blog",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        },
        {
          "url": "https://gpai.ai/projects/responsible-ai/AI-for-public-good-drug-discovery.pdf",
          "title": "AI for Public Good Drug Discovery",
          "summary": "International initiative framework for responsible AI deployment in public health drug discovery.",
          "documentType": "PDF",
          "retrievedAt": "2025-06-11",
          "sourceUsed": true
        }
      ],
      "findings": "Lilly's public commitments to AI are evidenced by its partnerships and participation in international responsible AI initiatives. These sources demonstrate transparency and external engagement in AI for public good and auditability."
    }
  },
  "aggregate": {
    "totalScoreOutOf7": 7,
    "percentScore": 100.0,
    "starRating": 5
  },
  "summary": {
    "starString": "★★★★★",
    "keyStrengths": [
      "Transparency",
      "Fairness & Bias Mitigation",
      "Explainability",
      "Human Oversight & Accountability",
      "Privacy & Security",
      "Governance & Accountability",
      "Public Commitments & External Audits"
    ],
    "keyGaps": [],
    "sourcesUsed": [
      {
        "url": "https://www.lilly.com/who-we-are/about-lilly/position-statements",
        "title": "Lilly's Position Statements",
        "summary": "Lilly's AI policy positions and transparency principles for stakeholder engagement.",
        "documentType": "Blog",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://sustainability.lilly.com/governance/business-ethics",
        "title": "Business Ethics - Lilly Sustainability Report",
        "summary": "Corporate ethics framework including AI transparency and responsible usage guidelines.",
        "documentType": "ESG Report",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://investor.lilly.com/static-files/17ef82ba-c9fb-482d-a5e1-81ee1f25c634",
        "title": "2025 Proxy Statement - Eli Lilly Investors",
        "summary": "Corporate governance document discussing responsible AI use and exploration initiatives.",
        "documentType": "PDF",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10764412/",
        "title": "Fairness of artificial intelligence in healthcare: review and recommendations",
        "summary": "Comprehensive fairness framework for AI in healthcare with bias mitigation strategies.",
        "documentType": "PDF",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://www.linkedin.com/posts/emerj_ai-ml-pharmaceuticals-activity-7283188343213821952-eVt6",
        "title": "Artificial Intelligence at Eli Lilly and Company",
        "summary": "Lilly's AI initiatives in content automation and drug discovery applications.",
        "documentType": "Blog",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12129466/",
        "title": "Explainable Artificial Intelligence in the Field of Drug Research",
        "summary": "Systematic analysis of explainable AI techniques and applications in pharmaceutical research.",
        "documentType": "PDF",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://sustainability.lilly.com/social/employee-experience",
        "title": "Employee Experience - Lilly Sustainability Report",
        "summary": "AI learning platforms and human-technology integration for employee development.",
        "documentType": "ESG Report",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://docs.publicnow.com/viewDoc.aspx?filename=99417%5CEXT%5C03794493456629B83A56AA1D04832FA1FE074455_AAB84A7D52E7FE524434E7C39AB8AC03EBADF81B.PDF",
        "title": "Application of AI in a GMP / Manufacturing environment",
        "summary": "Guidelines for human oversight requirements in AI-enabled pharmaceutical manufacturing processes.",
        "documentType": "PDF",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://privacynotice.lilly.com",
        "title": "Privacy Statement - Eli Lilly and Company",
        "summary": "Comprehensive privacy policy explicitly addressing AI data processing and compliance requirements.",
        "documentType": "Blog",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-appoints-thomas-j-fuchs-companys-first-chief-ai-officer",
        "title": "Lilly appoints Thomas J. Fuchs as the company's first chief AI officer",
        "summary": "Chief AI Officer appointment announcement outlining AI governance and security leadership.",
        "documentType": "Blog",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://www.ispe.gr.jp/ISPE/02_katsudou/pdf/202302_en.pdf",
        "title": "AI GOVERNANCE AND QA FRAMEWORK",
        "summary": "Comprehensive AI governance framework for pharmaceutical quality management systems.",
        "documentType": "PDF",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://talkingmedicines.com/2024/12/top-8-governance-considerations-for-ai-in-pharma/",
        "title": "Top 8 Governance Considerations for AI in Pharma",
        "summary": "Essential governance considerations for responsible AI implementation in pharmaceutical industry.",
        "documentType": "Blog",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://investor.lilly.com/news-releases/news-release-details/lilly-collaborates-openai-discover-novel-medicines-treat-drug",
        "title": "Lilly collaborates with OpenAI to discover novel medicines",
        "summary": "Public partnership announcement demonstrating AI collaboration commitment for global health challenges.",
        "documentType": "Blog",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      },
      {
        "url": "https://gpai.ai/projects/responsible-ai/AI-for-public-good-drug-discovery.pdf",
        "title": "AI for Public Good Drug Discovery",
        "summary": "International initiative framework for responsible AI deployment in public health drug discovery.",
        "documentType": "PDF",
        "retrievedAt": "2025-06-11",
        "sourceUsed": true
      }
    ],
    "overallFindings": "Eli Lilly and Company demonstrates comprehensive responsible AI practices across all seven pillars, with detailed and verifiable evidence for transparency, fairness, explainability, human oversight, privacy, governance, and public commitments. The company provides concrete documentation and public disclosures on its AI policies, governance frameworks, and collaborative initiatives. No significant gaps were identified, and the evidence reflects a mature and well-documented approach to responsible AI. Overall, Eli Lilly sets a strong example for responsible AI in the pharmaceutical industry."
  }
}